Kailera Therapeutics (KLRA) Stock Price, News & Analysis
Company Description
Kailera Therapeutics, Inc. is a clinical-stage biotechnology company developing product candidates for obesity care. The company is focused on a pipeline intended to provide treatment options for people living with obesity, with development work centered on GLP-1 based mechanisms of action and multiple routes of administration. Its common stock trades on the Nasdaq Global Select Market under the symbol KLRA.
The company describes an obesity-first development strategy built around four clinical-stage product candidates. Its pipeline focus places Kailera in the biotechnology segment of metabolic and obesity therapeutics, where company value is tied to the advancement, regulatory development, financing, and potential commercialization of investigational medicines rather than to an established commercial product portfolio.
Kailera operates as a public operating company headquartered in Waltham, Massachusetts. The company completed its initial public offering in April 2026, selling common stock and listing on Nasdaq. Public-company records identify Kailera as an emerging growth company and show a Delaware corporate structure with common stock registered under Section 12(b) of the Exchange Act.
As a newly public clinical-stage biotechnology issuer, Kailera's corporate profile is defined by its obesity-focused research and development activities, equity-financed capital structure, public-market listing, and governance framework for a development-stage life sciences company.
Stock Performance
Kailera Therapeutics (KLRA) stock last closed at $16.23. Over the past month, the stock has lost 10.4%. At a market capitalization of $2.1B, KLRA is classified as a mid-cap stock with approximately 129.6M shares outstanding.
KLRA Rankings
Latest News
Kailera Therapeutics has 10 recent news articles. Of the recent coverage, 4 articles coincided with positive price movement and 5 with negative movement. Key topics include earnings, clinical trial, IPO, offering. View all KLRA news →
SEC Filings
Kailera Therapeutics has filed 5 recent SEC filings, including 3 Form SCHEDULE 13G, 1 Form 10-Q, 1 Form 8-K. The most recent filing was submitted on August 14, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all KLRA SEC filings →
Financial Highlights
Upcoming Events
Global Phase 2 readout
Ribupatide Phase 3 start
High-dose Phase 2b data
KaiNETIC Phase 3 data
Kailera Therapeutics has 4 upcoming scheduled events. The next event, "Global Phase 2 readout", is scheduled for January 1, 2027 (in 117 days). Investors can track these dates to stay informed about potential catalysts that may affect the KLRA stock price.
Short Interest History
Short interest in Kailera Therapeutics (KLRA) currently stands at 6.1 million shares, down 8.5% from the previous reporting period, representing 6.9% of the float. Since April 2026, short interest has increased by 210.3%. With 20.1 days to cover, it would take significant time for short sellers to close their positions based on average trading volume.
Days to Cover History
Days to cover for Kailera Therapeutics (KLRA) currently stands at 20.1 days, up 51.8% from the previous period. This elevated days-to-cover ratio indicates it would take over two weeks of average trading volume for short sellers to exit their positions, suggesting potential for a short squeeze if positive news emerges. The days to cover has increased 1646.1% over the past year, indicating either rising short interest or declining trading volume. The ratio has shown significant volatility over the period, ranging from 1.1 to 20.1 days.
KLRA Company Profile & Sector Positioning
Kailera Therapeutics (KLRA) operates in the Biotechnology industry within the broader Pharmaceutical Preparations sector and is listed on the NASDAQ. In monthly performance, the stock ranks #4,154 among all tracked companies.